

Supplementary Table 1 | TACE procedure-related parameters in the three groups

Parameters	T+L+C (n=57)	T+C (n=41)	TACE (n=43)	P value
TACE technology				0.481
cTACE	39(68.4%)	29(70.7%)	34(79.1%)	
DEB-TACE	18(31.6%)	12(29.3%)	9(20.9%)	
Number of TACE	4.0(3.0,5.0)	4.0(3.0,5.0)	3.0(2.0,4.0)	0.001
Average days between TACE sessions	78.3(55.5,124.1)	70.2(50.4,99.3)	62.0(45.0,81.7)	0.034
Iodized oil dosage	10.0(10.0,15.0)	10.0(5.0,10.0)	10.0(10.0,15.0)	
Chemotherapy drugs				
Pirarubicin	30.0(20.0,40.0)	30.0(20.0,35.0)	30.0(30.0,30.0)	0.879
Lobaplatin	50.0(0.0,50.0)	50.0(35.0,50.0)	50.0(50.0,50.0)	0.015
Raltitrexed	2.0(0.0,2.0)	2.0(0.0,2.0)	2.0(2.0,2.00)	0.190
Laboratory metrics before treatment				
AST	51.0(36.0,84.5)	44.0(32.0,64.0)	54.0(39.0,83.0)	0.219
ALT	37.0(26.0,55.5)	34.0(24.0,50.0)	37.0(26.0,52.0)	0.677
TB	20.8(15.2,24.6)	18.6(13.0,32.1)	20.1(16.9,28.1)	0.693
ALB	38.98±5.11	39.39±4.70	39.38±3.93	0.880
Laboratory metrics after treatment				
AST	56.0(45.0,140.0)	72.0(45.0,120.5)	58.0(39.9,97.0)	0.276
ALT	46.0(30.0,103.0)	40.0(27.0,94.5)	30.0(23.0,44.0)	0.014
TB	27.2(19.9,34.8)	25.5(18.4,50.5)	26.7(17.9,37.4)	0.719
ALB	35.98±5.05	36.81±4.57	36.68±4.30	0.634

Data are presented as mean ± standard deviation or n (%) or median (25th-75th), cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TB, total bilirubin; ALB, albumin. T+L+C, transarterial chemoembolization combined with lenvatinib plus camrelizumab; T+C, transarterial chemoembolization combined with camrelizumab; TACE, transarterial chemoembolization.

Supplementary Table 2 | Subsequent treatment after progression.

	T+L+C (n=35)	T+C (n=34)	TACE (n=38)
TACE+Lenvatinib+Camrelizumab	3	0	0
Lenvatinib+ Camrelizumab	5	3	3
Lenvatinib	4	6	7
Apatinib	4	1	0
Donafenib	2	1	0
Regorafenib	4	0	0
Radiotherapy	1	0	0
HAIC	0	5	0
TACE+ Camrelizumab	0	3	0
Camrelizumab r	0	0	2
TACE+Lenvatinib	0	0	2
TACE+ Sorafenib	0	0	1
Sorafenib	0	0	7
Sorafenib+ Camrelizumab	0	0	2
TACE	3	6	3
Supportive Care	7	7	6
Abandonment of treatment	2	2	5

TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion of chemotherapy.